[Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].
A control-case study conducted in 56 patients, all diagnosed with benign prostate hypertrophy of which 36 were Prazosin-treated patients and the remaining 20 were controls. The patient's mictional signs and symptoms as well as flow parameters were monitored at 3 and 6 months, respectively. We conclude that Prazosin is an alpha-blocker useful in early prostate disorders and when no obstructive urological disease is present.
Adriazola Semino
M
M
Servicio de Urología, Hospital Rio Carrion, Palencia.
García Cobo
E
E
De la Calle Muñoz
I
I
Tejeda Bañez
E
E
Romero
F
F
D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D011224:Prazosin